A randomized trial comparing vaginal laser therapy and pelvic floor physical therapy for treating women with stress urinary incontinence

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
GIARRETA, Fernanda Bacchi Ambrosano
LOCALI, Priscila Katsumi Matsuoka
Citação
NEUROUROLOGY AND URODYNAMICS, v.42, n.7, p.1445-1454, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IntroductionFemale stress urinary incontinence (SUI) is considered a major public health issue. Physical therapy is an important conservative treatment; however, it is primarily limited by poor long-term compliance. Furthermore, surgical treatment entails significant risks. Therefore, new treatment techniques must be identified. ObjectiveTo compare the use of laser therapy and pelvic floor (PF) physical therapy for treating postmenopausal women with SUI. MethodsThis pilot study enrolled 40 women with a clinical and urodynamic diagnosis of SUI who were randomized into two groups: those who received erbium-doped yttrium-aluminum-garnet (Er:YAG) laser therapy implemented over three sessions with a 1-month interval (n = 20) and those who received physical therapy with supervision twice a week for 3 months (n = 20). In total, 16 women completed the treatment in each group. The patients were assessed for PF function using the modified Oxford scale and for pelvic organ prolapse using the Pelvic Organ Prolapse Quantification System. The 1-h pad test and quality of life questionnaires, King's Health Questionnaire (KHQ), and Incontinence Quality of Life (IQOL) were also administered. Patients were re-evaluated at 1, 3, 6, and 12 months after treatment. ResultsThe mean patient age was 62.7 & PLUSMN; 9.1 and 57.9 & PLUSMN; 6.1 years, median Oxford score at baseline was 3 (2-4.5) and 4 (3-4), mean IQOL score was 79.8 & PLUSMN; 17 and 74.6 & PLUSMN; 18 for physical therapy group (PTG) and laser group (LG), respectively. For the amount of urine leak in the 1-h pad test evaluation, we found significance for the interaction of group and time points only for the Laser intragroup. The cure rate, that is, the rate of reaching an insignificant score in the pad test, at 6 and 12 months was 43.75% and 50% in PTG and 62.5% and 56.25% in the LG, respectively (p > 0.05). IQOL scores demonstrated considerable improvement in both groups (p > 0.05). Upon comparing the initial and follow-up results, the LG showed an improvement at all consultations, whereas the PTG showed improvements at 1, 3, and 6 months but not at 12 months after treatment. KHQ analysis revealed a considerable improvement in the quality of life (QOL) of patients over time, with no substantial difference between the groups. QOL comparison before and after treatment revealed that the vaginal LG improved more consistently in some domains. Only the PTG showed a significant increase in the mean Oxford score from pretreatment to 1 and 3 months after treatment (p < 0.001 and p = 0.002, respectively). However, no statistically significant difference was observed between the groups. ConclusionBoth treatments are safe and have a positive influence on the impact of UI on patients' QOL. The laser caused a greater reduction in the urinary loss, as measured using the weight of pad test, at 6-month and 12-month after treatment without difference with PTG at the end of the follow-up.
Palavras-chave
exercise, laser, pelvic floor, physical therapy, stress urinary incontinence, urinary incontinence
URI
https://observatorio.fm.usp.br/handle/OPI/58869
Referências
  1. Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
  2. Alouini S, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19052789
  3. Alsulihem A, 2021, INT UROGYNECOL J, V32, P553, DOI 10.1007/s00192-020-04548-2
  4. Athanasiou S, 2019, MENOPAUSE, V26, P248, DOI 10.1097/GME.0000000000001206
  5. Ayeleke RO., 2015, COCHRANE DB SYST REV, V2015
  6. Blaganje M, 2018, EUR J OBSTET GYN R B, V224, P153, DOI 10.1016/j.ejogrb.2018.03.038
  7. Bump RC, 1996, AM J OBSTET GYNECOL, V175, P10, DOI 10.1016/S0002-9378(96)70243-0
  8. Chen BH, 2002, INT UROGYNECOL J, V13, P80, DOI 10.1007/s001920200020
  9. Collins SA, 2020, INT UROGYNECOL J, V31, P465, DOI 10.1007/s00192-020-04237-0
  10. Souza CCC, 2009, INT UROGYNECOL J, V20, P1183, DOI 10.1007/s00192-009-0916-8
  11. Zanetti MRD, 2007, SAO PAULO MED J, V125, P265, DOI 10.1590/S1516-31802007000500003
  12. Dumoulin C, 2011, NEUROUROL URODYNAM, V30, P746, DOI 10.1002/nau.21104
  13. Oliveira MCE, 2020, NEUROUROL URODYNAM, V39, P1592, DOI 10.1002/nau.24350
  14. FALCONER C, 1994, OBSTET GYNECOL, V84, P583
  15. Fistonic N, 2016, LASER MED SCI, V31, P635, DOI 10.1007/s10103-016-1884-0
  16. Franic D, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1576359
  17. GILPIN SA, 1989, BRIT J OBSTET GYNAEC, V96, P15, DOI 10.1111/j.1471-0528.1989.tb01570.x
  18. Haylen BT, 2010, INT UROGYNECOL J, V21, P5, DOI 10.1007/s00192-009-0976-9
  19. Imamura M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003505.pub5
  20. Lapii GA, 2017, B EXP BIOL MED+, V162, P510, DOI 10.1007/s10517-017-3650-0
  21. Laycock J., 1994, J NATL WOMEN HLTH GR, P40
  22. Fonseca ESM, 2005, REV BRAS GINECOL OBS, V27, P235, DOI 10.1590/S0100-72032005000500002
  23. Tsai YC, 2009, INT J NURS STUD, V46, P1181, DOI 10.1016/j.ijnurstu.2009.03.003
  24. Vizintin Z., 2012, LA HA J, V1, P46
  25. Yao M., 2023, URODYNAMIC TESTING I

Coleções
Artigos e Materiais de Revistas Científicas - FM/MFT